Phase 3 Epilepsy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been officially diagnosed with a developmental and epileptic encephalopathy (a brain condition that causes both developmental challenges and seizures).
- Your seizures first started before the age of 12.
- You weigh more than 7 kg (about 15.4 lbs) at the time of signing the consent form.
Who may not be able to join:
- You have a history of certain heart conditions, including left bundle branch block, irregular heart rhythms, Brugada syndrome, a heart condition present from birth, familial short QT syndrome, or a family history of sudden death or serious irregular heart rhythms.
- You have had 2 or more episodes of severe, prolonged seizures (called convulsive status epilepticus) that required a hospital stay and breathing support (a breathing tube) in the 6 months before the screening visit.
- Your heart electrical activity reading (called an ECG) shows an abnormal result at screening or at your first study visit (confirm with trial site).
- If you use a nerve stimulation device, it must have been put in place at least 3 months before screening, and the settings must have been stable for at least 1 month before screening.
- You have taken part in another experimental drug or device study, or received gene therapy, within the past 30 days or within 5 half-lives of that drug (whichever is longer) before screening.
- You are currently pregnant, breastfeeding, or planning to become pregnant during the trial or shortly after finishing the study drug.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Praxis Precision Medicines
Phone: 617-300-8460
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
To assess the effect of relutrigine on seizure frequency in participants with DEEs compared to placebo
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.